Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Inflammatory Genodermatoses
NCT06136403Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deucravacitinib in epidermolysis bullosa simplex (EBS), ichthyosis, Genodermatosis, congenital ichthyosis, sponsored by Centre Hospitalier Universitaire de Nice. Started Mar 2024; status: completed.
02
Drugs
deucravacitinib
03
Conditions
epidermolysis bullosa simplex (EBS)ichthyosisGenodermatosiscongenital ichthyosis
Beyond the preview
Go deeper on NCT06136403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136403.